Analyzing Mind Medicine (MindMed) (NASDAQ: MNMD) and Mannatech (NASDAQ: MTEX)


Mind Medicine (MindMed) (NASDAQ: MNMDGet Rating) and Mannatech (NASDAQ: MTEXGet Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Mind Medicine (MindMed) and Mannatech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) ON -55.27% -51.10%
Mannatech 6.16% 39.51% 15.62%

Insider and Institutional Ownership

12.4% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 32.0% of Mannatech shares are held by institutional investors. 45.8% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mind Medicine (MindMed) and Mannatech, as reported by MarketBeat.com.

Sell ​​Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 3 0 3.00
Mannatech 0 0 0 0 ON

Mind Medicine (MindMed) currently has a consensus target price of 7.67, suggesting a potential upside of 882.91%. Given Mind Medicine (MindMed) ‘s higher probable upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Mannatech.

Earnings & Valuation

This table compares Mind Medicine (MindMed) and Mannatech’s gross revenue, earnings per share and valuation.

Gross Revenue Price / Sales Ratio Net Income Earnings Per Share Price / Earnings Ratio
Mind Medicine (MindMed) ON ON – $ 93.04 million -0.23 -3.39
Mannatech $ 159.76 million 0.33 $ 9.84 million $ 4.72 5.76

Mannatech has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Summary

Mannatech beats Mind Medicine (MindMed) on 9 of the 11 factors compared between the two stocks.

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

About Mannatech (Get Rating)

Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.



Receive News & Ratings for Mind Medicine (MindMed) Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.